Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00845195 · ClinicalTrials.gov registry record · Phase 4

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

A Phase 4 study of Seasonal Allergic Rhinitis, sponsored by Alcon Research.

Completed
Registry status
Phase 4
Development phase
150
Enrollment target
1
Study location

NCT00845195 is a Phase 4 study of Seasonal Allergic Rhinitis that has completed, run by Alcon Research. The registered enrollment target is 150 participants, below the 659-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00845195, a Phase 4 study of Seasonal Allergic Rhinitis, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 4
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the efficacy of Olopatadine Nasal Spray with Azelastine Nasal Spray when treatments are utilized in conjunction with Fluticasone Nasal Spray for the treatment of seasonal allergic rhinitis.

Conditions Studied

Interventions

  • DRUG Olopatadine HCl Nasal Spray, 0.6%
  • DRUG Azelastine HCl Nasal Spray, 0.1%

Study Locations (1)

Texas

  • Alcon Call Center for Trial Locations - Fort Worth

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2009-03
Phase Phase 4

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT00845195

The ClinicalTrials.gov registry entry for NCT00845195 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (77% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Olopatadine HCl Nasal Spray, 0.6% is the first listed.

NCT00845195 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00845195 about?

NCT00845195 is a clinical study titled "Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid". The purpose of this study is to compare the efficacy of Olopatadine Nasal Spray with Azelastine Nasal Spray when treatments are utilized in conjunction with Fluticasone Nasal Spray for the treatment of seasonal allergic rhinitis.

What is the current status of trial NCT00845195?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2009-03.

What conditions does trial NCT00845195 study?

This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.

What interventions are being tested in trial NCT00845195?

The interventions under investigation include: Olopatadine HCl Nasal Spray, 0.6% (DRUG), Azelastine HCl Nasal Spray, 0.1% (DRUG).

Who is sponsoring clinical trial NCT00845195?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00845195 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Seasonal Allergic Rhinitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.